The Mediterranean Journal of Hematology and Infectious Diseases: A New Milestone and a Hope for Researchers in Third World Countries

JNawfal R Hussein.

Department of Biomedical Sciences, The College of Medicine, University of Zakho, Kurdistan Region of Iraq.

Correspondence to: Nawfal R Hussein. Room 94, Main building, University campus, The department of biomedical sciences, The College of Medicine, University of Zakho, Kurdistan Region of Iraq. E-mail: Nawfal.hussein@yahoo.com 

Published: May 1, 2022
Received: March 15, 2022
Accepted: April 5, 2022
Mediterr J Hematol Infect Dis 2022, 14(1): e2022035 DOI 10.4084/MJHID.2022.035

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the editor

We learned with pleasure that The Mediterranean Journal of Hematology and Infectious Diseases had hit a new milestone by obtaining an impact factor of 2.576. We want to congratulate you on this achievement. From our point of view, in a country with poor resources and enthusiastic researchers, the MJHID was a shelter for our papers. This Journal provides three advantages for us. Firstly, English language weakness does not influence the decision, and secondly, it provides a good guide to the researcher to build a good quality project. Thirdly, the communication with the Editor is straightforward without obstacles. Utilizing such advantages, we could have published good papers in the MJHID, gaining readers’ attention and recording good citations.[1-5] It is believed that the advantages the MJHID provided to authors have played a role in hitting such a milestone. The new Journal’s achievement should not change its standards to continue encouraging us all the researchers of low-income countries. Therefore, we believe that hitting a new milestone should drive you to increase the help to researchers in the low-income research setting and where the research resources are sparse. We suggest the Journal establish a mentoring committee to help such researchers meet international standards and make necessary amendments to the projects rather than rejecting the papers in the first screening and/or revision round. Finally, in a world full of challenges for researchers who work in an environment that does not appreciate and support research, we hope to support and provide a platform that makes our voice heard.


References   

  1. Hussein NR. The efficacy and safety of sofosbuvir-containing regimen in the treatment of HCV infection in patients with haemoglobinopathy. Mediterranean Journal of Hematology and Infectious Diseases. 2017;9(1) :e2017005. https://doi.org/10.4084/mjhid.2017.005 PMid:28105296 PMCid:PMC5224801
  2. Hussein NR, Naqid IA, Saleem ZSM. A retrospective descriptive study characterizing coronavirus disease epidemiology among people in the Kurdistan Region, Iraq. Mediterranean Journal of Hematology and Infectious Diseases. 2020;12(1):e2020061. https://doi.org/10.4084/mjhid.2020.061 PMid:32952972 PMCid:PMC7485477
  3. Hussein NR, Naqid IA, Salih HM. The efficacy and safety of intralesional sodium stibogluconate for the treatment of cutaneous Leishmaniasis in children under the age of two years. Mediterranean Journal of Hematology and Infectious Diseases. 2020;12(1) :e2020027. https://doi.org/10.4084/mjhid.2020.027 PMid:32395216 PMCid:PMC7202348
  4. Hussein NR, Rashad BH, Almizori LA, Yousif SS, Sadeeq AT, Abdulkareem YR, et al. The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan region of Iraq. Mediterranean Journal of Hematology and Infectious Diseases. 2021;13(1):e2021035. https://doi.org/10.4084/MJHID.2021.035 PMid:34007423 PMCid:PMC8114888
  5. Hussein NR, Saleema ZS, Abd QH. Direct acting antiviral treatment for patients with end-stage kidney disease with acute HCV infection. Mediterranean Journal of Hematology and Infectious Diseases. 2019;11(1):e2019034. https://doi.org/10.4084/mjhid.2019.034 PMid:31205638 PMCid:PMC6548205

[TOP]